India is likely to participate in the World Health Organisation's (WHO) 'solidarity trial' for a potential treatment for COVID-19.
Addressing a press conference here, Dr R Ganga Ketkar of Indian Council of Medical Research (ICMR) said: "We are likely to start our participation soon in solidarity trial that the WHO is starting."
"Earlier we did not do it because our numbers were so small that our contribution would have looked minuscule," added Ketkar.
The WHO is starting a multi-country clinical study for the potential treatment of COVID-19, part of a rapid global search for drugs to treat COVID-19.
A total of 724 confirmed cases of COVID-19 have been reported in India, the Ministry of Health and Family Welfare said on Friday.
"Till now 724 COVID-19 cases have been confirmed and total deaths stand at 17. In the last 24 hours, 75 new positive cases and 4 deaths have been reported," said Lav Aggarwal, Joint Secretary, Union Health Ministry.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app